This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna (MRNA) Starts Early-Stage Nipah Virus Vaccine Study
by Zacks Equity Research
Moderna (MRNA) doses the first participant in the phase I study of its investigational mRNA vaccine, targeting the Nipah virus. It also starts a mid-stage study evaluating its Zika virus vaccine.
Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug
by Zacks Equity Research
Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.
Best Momentum Stocks to Buy for July 13th
by Zacks Equity Research
JAZZ, GKOS and SPPI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2022.
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Drugmaker Stocks Worth Buying to Boost Your Portfolio Health
by Kinjel Shah
Merck (MRK), Bayer (BAYRY) and Jazz Pharmaceuticals (JAZZ) are three large drugmakers that are good stocks to buy.
How Much Upside is Left in Jazz (JAZZ)? Wall Street Analysts Think 28%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.5% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ProPhase Labs, Inc. (PRPH) Soars 9.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
JAZZ vs. STVN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
JAZZ vs. STVN: Which Stock Is the Better Value Option?
Axsome (AXSM) Hurt by Regulatory Setbacks: Will It Recover?
by Zacks Equity Research
Axsome's (AXSM) extension of the review period for AXS-05 NDA and CRL for AXS-07 NDA hurt prospects. However, recent positive updates on AXS-05 are driving positive sentiments.
JAZZ's Late-Stage Multiple Sclerosis Study on Nabiximols Fails
by Zacks Equity Research
JAZZ's phase III study evaluating nabiximols oromucosal spray for clinical measures of spasticity in multiple sclerosis patients fails to meet the primary endpoint.
Axsome (AXSM) Surges Following FDA Label Proposal for AXS-05
by Zacks Equity Research
Axsome (AXSM) receives proposed labeling from the FDA for its under-review depression drug candidate, AXS-05, implying a potential approval soon. Shares surge more than 50%.
Are Options Traders Betting on a Big Move in Jazz Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Investors need to pay close attention to Jazz Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Jazz (JAZZ) Down 1.5% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review
by Zacks Equity Research
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ImmunoGen (IMGN) Q1 Earnings and Sales Outpace Estimates
by Zacks Equity Research
ImmunoGen (IMGN) reports a narrower-than-expected loss for first-quarter 2022. It also beats revenue estimates.
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Vision Care with the addition of new products and recent acquisition is likely to have contributed to Alcon's (ALC) first-quarter performance.
STERIS (STE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Healthcare and AST arms is expected to have driven STERIS' (STE) fourth-quarter revenues.
JAZZ Q1 Earnings Miss, Sales Robust, 2022 Guidance Raised
by Zacks Equity Research
JAZZ's product revenues grow in the first quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. It raises guidance on strong results.
Jazz Pharmaceuticals (JAZZ) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of -0.53% and 4.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Onconova (ONTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will watch for updates on its lead candidate narazaciclib when Onconova Therapeutics. (ONTX) reports first-quarter earnings.
Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q1 earnings might have been adversely impacted by competition in the complex generics business.